Form 4: Korro Bio Director Receives Stock Option Grant

Director Nessan Bermingham was granted 14,677 stock options in Korro Bio, Inc. as part of a standard equity compensation package.

Summary

• Director Nessan Bermingham received a grant of 14,677 stock options for Korro Bio, Inc. (KRRO) common stock.
• The options have an exercise price of $10.59 per share.
• The grant date for these options is June 10, 2026.
• The options are set to expire on June 9, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $10.59 exercise price.

Future Outlook

The options vest in full on the earlier of the one-year anniversary of the grant date or the date of the next annual meeting of stockholders, contingent upon continued service.

Management Comments

• No specific management commentary provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board talent, aligning leadership with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The vesting schedule (one year or next annual meeting) is consistent with standard corporate governance practices for non-employee director compensation in mid-cap biotech firms.

Stakeholder Impact

• Minor potential dilution for existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on the earlier of June 10, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

Korro Bio, KRRO, Director Compensation, Stock Options, Insider Transaction, Biotech